ABT-110 is a human monoclonal antibody targeting NGF/bNGF. It has been shown to alleviate established thermal and mechanical hypersensitivity reactions in a CFA rat model. ABT-110 is applicable for research on persistent or chronic inflammatory pain.
Target-Kategorie:
Trk receptor
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
